Trailing Twelve Months Revenue Growth: Contineum Corp (CTNM)

Brandmark of Contineum Therapeutics, Inc. (CTNM)

Contineum Therapeutics, Inc. (CTNM) maintains a business model resilient to market volatility due to its liquidity reserves and independence from economic cycles. Its development pipeline leverages a modern molecular biology foundation and external synthetic partners. However, the risk of clinical trial failure creates fierce competition for patents. Year-over-year sales dynamics for the last four quarters on the GURU.Markets chart show that the indicator value reaches 0.00.

Contineum Therapeutics, Inc. (CTNM): Revenue Growth YoY (Last 12 Months) from 11/23/2025 to 11/18/2026

Summary analytical data breakdowns for Contineum Corp (CTNM)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Analysis of all company metrics:Contineum Therapeutics, Inc. - CTNM
Mass-produced product of Contineum Pharma

To isolate the fundamental stability of Contineum Therapeutics, Inc. (CTNM) from market noise, it is critical to analyze revenue changes over the last 12 months relative to the same period last year. The annual trend in sales receipts over four quarters reflects the actual pace of business expansion, which, combined with the implementation of eco-friendly technical processes and ethical drug development standards, confirms the company's long-term viability and responsibility.